MAP2K7 and colorectal carcinoma: To verify the results of the kinome-centered genetic screen, we additionally conducted a mini-screen using chemical inhibitors specifically targeting EGFR, MEK, mTOR, phosphoinositide 3-kinase (PI3K), SHP2, or CDK4/6, which are key factors associated with drug tolerance in CRC [31–34].